MedTrace Logo

Prevention Of Recurrence Of Atrial Fibrillation

NCT00041496 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2014-08-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

Conditions

  • Fibrillation, Atrial

Interventions

DRUG

SB-207266

White, oval, biconvex tablets containing either 10mg, 25mg or 40mg

OTHER

Placebo

Placebo to match SB-207266

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2003-12-31
Completion
2003-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00041496 on ClinicalTrials.gov